NO20032142L - Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister - Google Patents

Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister

Info

Publication number
NO20032142L
NO20032142L NO20032142A NO20032142A NO20032142L NO 20032142 L NO20032142 L NO 20032142L NO 20032142 A NO20032142 A NO 20032142A NO 20032142 A NO20032142 A NO 20032142A NO 20032142 L NO20032142 L NO 20032142L
Authority
NO
Norway
Prior art keywords
phenylaminoimidazoline
antagonists
substituted
phenylketone derivatives
phenylketone
Prior art date
Application number
NO20032142A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032142D0 (no
Inventor
Alam Jahangir
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20032142L publication Critical patent/NO20032142L/no
Publication of NO20032142D0 publication Critical patent/NO20032142D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/50Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
NO20032142A 2000-11-14 2003-05-13 Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister NO20032142D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24888800P 2000-11-14 2000-11-14
PCT/EP2001/012776 WO2002040453A1 (en) 2000-11-14 2001-11-05 Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists

Publications (2)

Publication Number Publication Date
NO20032142L true NO20032142L (no) 2003-05-13
NO20032142D0 NO20032142D0 (no) 2003-05-13

Family

ID=22941114

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032142A NO20032142D0 (no) 2000-11-14 2003-05-13 Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister

Country Status (29)

Country Link
EP (1) EP1339694B1 (ru)
JP (1) JP4108474B2 (ru)
KR (1) KR100562605B1 (ru)
CN (1) CN1267423C (ru)
AR (1) AR035502A1 (ru)
AT (1) ATE305002T1 (ru)
AU (1) AU2180802A (ru)
BG (1) BG107814A (ru)
BR (1) BR0115291A (ru)
CA (1) CA2427900A1 (ru)
CZ (1) CZ20031596A3 (ru)
DE (1) DE60113563T2 (ru)
EC (1) ECSP034602A (ru)
ES (1) ES2248413T3 (ru)
HU (1) HUP0303156A3 (ru)
IL (1) IL155436A0 (ru)
MA (1) MA26958A1 (ru)
MX (1) MXPA03004073A (ru)
NO (1) NO20032142D0 (ru)
NZ (1) NZ525330A (ru)
PA (1) PA8532201A1 (ru)
PE (1) PE20020602A1 (ru)
PL (1) PL362549A1 (ru)
RU (1) RU2284995C2 (ru)
SK (1) SK7222003A3 (ru)
UY (1) UY27023A1 (ru)
WO (1) WO2002040453A1 (ru)
YU (1) YU37203A (ru)
ZA (1) ZA200303413B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517576A (ja) * 2003-02-14 2006-07-27 メディカル リサーチ カウンシル 病理的子宮症状の治療のためのipレセプターアンタゴニスト
MXPA05011476A (es) * 2003-05-01 2005-12-12 Hoffmann La Roche Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2.
WO2005000247A2 (en) * 2003-06-25 2005-01-06 Smithkline Beecham Corporation 4-carboxamido quinoline derivatives for use as nk-2 and nk-3
MXPA06000269A (es) * 2003-07-09 2006-04-07 Hoffmann La Roche Tiofenilaminoimidazolinas.
JP2009524619A (ja) * 2006-01-27 2009-07-02 エフ.ホフマン−ラ ロシュ アーゲー Cns障害の処置のための2−イミダゾールの使用
CA2666762C (en) 2006-10-19 2014-12-30 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
JP5064511B2 (ja) 2006-11-02 2012-10-31 エフ.ホフマン−ラ ロシュ アーゲー 痕跡アミン関連受容体調節剤としての置換2−イミダゾール
RU2456281C2 (ru) 2006-11-16 2012-07-20 Ф. Хоффманн-Ля Рош Аг Замещенные 4-имидазолы, способ их получения и их применение
AU2007332641A1 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (TAAR)
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
RU2473545C2 (ru) 2007-02-02 2013-01-27 Ф.Хоффманн-Ля Рош Аг Новые 2-аминооксазолины в качестве лигандов taar1 для заболеваний цнс
KR101335845B1 (ko) 2007-02-15 2013-12-02 에프. 호프만-라 로슈 아게 Taar1 리간드로서의 2-아미노옥사졸린
BRPI0812840A2 (pt) 2007-07-02 2014-12-09 Hoffmann La Roche 2-imidazolinas
JP2010531836A (ja) 2007-07-03 2010-09-30 エフ.ホフマン−ラ ロシュ アーゲー 4−イミダゾリン及びそれらの抗うつ剤としての使用
KR101133862B1 (ko) 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Taar 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
WO2009019149A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
WO2011080132A2 (en) 2009-12-17 2011-07-07 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2014143591A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
WO2014143592A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid ip receptors
US9827225B2 (en) * 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
MY195528A (en) 2016-03-17 2023-01-30 Hoffmann La Roche 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889868A (en) * 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
GB9506188D0 (en) * 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives
NZ331480A (en) * 1997-09-04 2000-02-28 F 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
YU37203A (sh) 2006-05-25
KR20030065512A (ko) 2003-08-06
EP1339694A1 (en) 2003-09-03
BG107814A (bg) 2004-02-27
CZ20031596A3 (cs) 2004-01-14
CA2427900A1 (en) 2002-05-23
CN1267423C (zh) 2006-08-02
DE60113563T2 (de) 2006-07-13
HUP0303156A3 (en) 2004-03-29
ATE305002T1 (de) 2005-10-15
NO20032142D0 (no) 2003-05-13
BR0115291A (pt) 2003-08-19
EP1339694B1 (en) 2005-09-21
ES2248413T3 (es) 2006-03-16
JP4108474B2 (ja) 2008-06-25
PE20020602A1 (es) 2002-07-08
WO2002040453A1 (en) 2002-05-23
NZ525330A (en) 2004-10-29
MA26958A1 (fr) 2004-12-20
MXPA03004073A (es) 2003-09-04
AR035502A1 (es) 2004-06-02
ZA200303413B (en) 2004-08-02
HUP0303156A2 (hu) 2004-01-28
AU2180802A (en) 2002-05-27
IL155436A0 (en) 2003-11-23
JP2004513940A (ja) 2004-05-13
RU2284995C2 (ru) 2006-10-10
PL362549A1 (en) 2004-11-02
DE60113563D1 (de) 2006-02-02
UY27023A1 (es) 2002-06-20
ECSP034602A (es) 2003-06-25
KR100562605B1 (ko) 2006-03-17
SK7222003A3 (en) 2004-05-04
PA8532201A1 (es) 2002-08-26
CN1474813A (zh) 2004-02-11

Similar Documents

Publication Publication Date Title
NO20032142D0 (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
NO20024387D0 (no) Karboksylsyrederivater som IP-antagonister
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
NO20030055L (no) Colchinolderivater som angiogenese inhibitorer
NO20043022L (no) 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
NO20023485D0 (no) 1,3-disubstituerte pyrrolidiner som alfa-2- adrenoceptorantagonister
NO20041235L (no) Kinolinderivater som neuropeptid Y antagonister
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DK1360184T3 (da) Piperidinderivater som neurokinin-1-antagonister
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
DK1368299T3 (da) Substituerede C-cyclohexylmethylaminderivater
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
DK1155013T3 (da) Heyterocycliske benzensulfonamidderivater som bradykininantagonister
ATE309994T1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
DK1322592T4 (da) Substituerede 1-aminobutan-3-ol-derivater
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
DK1406888T3 (da) Substituerede gamma-lactonforbindelser som NMDA-antagonister
DK1261588T3 (da) Imidazolforbindelser som alfa2-adrenoceptorantagonister
ATE361274T1 (de) Substituierte 5-amino-1-penten-3-ol-derivate
DE50104434D1 (de) Lactam-substituierte pyrazolopyridinderivate
DK1246793T3 (da) Substituerede aminomethyl-phenyl-cyclohexanderivater
DK1210333T3 (da) p-Tolylsubstituerede heterocycliske forbindelser som herbicider

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application